Xu Y, Huang XB, He YG. Radiotherapy combined with bevacizumab in gastrointestinal cancers: Balancing efficacy against the risk of intestinal perforation. World J Radiol 2026; 18(1): 116084 [DOI: 10.4329/wjr.v18.i1.116084]
Corresponding Author of This Article
Yong-Gang He, Associate Chief Physician, Department of Hepatobiliary Medicine, The Second Affiliated Hospital of Army Medical University, No. 83 Xinqiaozheng Street, Chongqing 400037, China. xqyyhyg@tmmu.edu.cn
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Jan 28, 2026 (publication date) through Jan 28, 2026
Times Cited of This Article
Times Cited (0)
Journal Information of This Article
Publication Name
World Journal of Radiology
ISSN
1949-8470
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Xu Y, Huang XB, He YG. Radiotherapy combined with bevacizumab in gastrointestinal cancers: Balancing efficacy against the risk of intestinal perforation. World J Radiol 2026; 18(1): 116084 [DOI: 10.4329/wjr.v18.i1.116084]
World J Radiol. Jan 28, 2026; 18(1): 116084 Published online Jan 28, 2026. doi: 10.4329/wjr.v18.i1.116084
Radiotherapy combined with bevacizumab in gastrointestinal cancers: Balancing efficacy against the risk of intestinal perforation
Yan Xu, Xiao-Bing Huang, Yong-Gang He
Yan Xu, Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital of Army Medical University, Chongqing 400037, China
Xiao-Bing Huang, Yong-Gang He, Department of Hepatobiliary Medicine, The Second Affiliated Hospital of Army Medical University, Chongqing 400037, China
Co-corresponding authors: Xiao-Bing Huang and Yong-Gang He.
Author contributions: Xu Y drafted and edited the manuscript; Huang XB and He YG contributed to the conceptualization of the study and the critical review of the manuscript for important intellectual content, and they contributed equally to this articl as the co-corresponding authors of this manuscript; and all authors have read and approved the final version of the manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yong-Gang He, Associate Chief Physician, Department of Hepatobiliary Medicine, The Second Affiliated Hospital of Army Medical University, No. 83 Xinqiaozheng Street, Chongqing 400037, China. xqyyhyg@tmmu.edu.cn
Received: November 2, 2025 Revised: November 15, 2025 Accepted: December 19, 2025 Published online: January 28, 2026 Processing time: 85 Days and 16.2 Hours
Abstract
The combination of radiotherapy with bevacizumab represents a promising therapeutic strategy for advanced gastrointestinal cancers. While this combination leverages synergistic mechanisms to enhance antitumor efficacy, it also poses significant safety concerns, particularly regarding the risk of intestinal perforation. This letter discusses the current understanding of this dual effect and underscores the importance of careful patient selection, advanced radiotherapy techniques, and vigilant toxicity monitoring to optimize clinical outcomes.
Core Tip: The combination of radiotherapy and bevacizumab in gastrointestinal cancers offers enhanced efficacy but requires careful management due to an increased risk of intestinal perforation. Strategic patient selection and advanced radiotherapy techniques are essential to balance benefits and risks.
